Indaptus Therapeutics (NASDAQ: INDP)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-14 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.480 | -0.460 | 0.0200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Indaptus Therapeutics (NASDAQ: INDP) through any online brokerage.
Other companies in Indaptus Therapeutics’s space includes: Biocept (NASDAQ:BIOC), Monopar Therapeutics (NASDAQ:MNPR), Cyclacel Pharmaceuticals (NASDAQ:CYCC), Calithera Biosciences (NASDAQ:CALA) and ABVC BioPharma (NASDAQ:ABVC).
The latest price target for Indaptus Therapeutics (NASDAQ: INDP) was reported by HC Wainwright & Co. on Monday, January 31, 2022. The analyst firm set a price target for 15.00 expecting INDP to rise to within 12 months (a possible 459.70% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Indaptus Therapeutics (NASDAQ: INDP) is $2.68 last updated Today at August 17, 2022, 7:50 PM UTC.
There are no upcoming dividends for Indaptus Therapeutics.
Indaptus Therapeutics’s Q3 earnings are confirmed for Monday, November 14, 2022.
There is no upcoming split for Indaptus Therapeutics.
Indaptus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.